Completed PHASE4 INTERVENTIONAL 2-arm NCT02237339

Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? (ALLAY)

Does Allopurinol Regress Left Ventricular Hypertrophy in Patients With Treated Essential Hypertension?

Sponsor: British Heart Foundation

Conditions Hypertension Hypertrophy, Left Ventricular

Updated 7 times since 2017 Last updated: Sep 13, 2019 Started: Sep 30, 2014 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02237339, this PHASE4 trial focuses on Hypertension and Hypertrophy, Left Ventricular and remains completed. Sponsored by British Heart Foundation, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Oct 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Oct 2019 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Nov 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Jan 2017 — Nov 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

British Heart Foundation
University of Dundee

Data source: University of Dundee

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dundee, United Kingdom